scholarly journals Minimal change in structural, functional and inflammatory markers of lung disease in newborn screened infants with cystic fibrosis at one year

2020 ◽  
Vol 19 (6) ◽  
pp. 896-901 ◽  
Author(s):  
Gwyneth Davies ◽  
Lena P Thia ◽  
Janet Stocks ◽  
Andrew Bush ◽  
Ah-Fong Hoo ◽  
...  
2019 ◽  
Vol 11 (486) ◽  
pp. eaav3488 ◽  
Author(s):  
Charles R. Esther ◽  
Marianne S. Muhlebach ◽  
Camille Ehre ◽  
David B. Hill ◽  
Matthew C. Wolfgang ◽  
...  

Although destructive airway disease is evident in young children with cystic fibrosis (CF), little is known about the nature of the early CF lung environment triggering the disease. To elucidate early CF pulmonary pathophysiology, we performed mucus, inflammation, metabolomic, and microbiome analyses on bronchoalveolar lavage fluid (BALF) from 46 preschool children with CF enrolled in the Australian Respiratory Early Surveillance Team for Cystic Fibrosis (AREST CF) program and 16 non-CF disease controls. Total airway mucins were elevated in CF compared to non-CF BALF irrespective of infection, and higher densities of mucus flakes containing mucin 5B and mucin 5AC were observed in samples from CF patients. Total mucins and mucus flakes correlated with inflammation, hypoxia, and oxidative stress. Many CF BALFs appeared sterile by culture and molecular analyses, whereas other samples exhibiting bacterial taxa associated with the oral cavity. Children without computed tomography–defined structural lung disease exhibited elevated BALF mucus flakes and neutrophils, but little/no bacterial infection. Although CF mucus flakes appeared “permanent” because they did not dissolve in dilute BALF matrix, they could be solubilized by a previously unidentified reducing agent (P2062), but notN-acetylcysteine or deoxyribonuclease. These findings indicate that early CF lung disease is characterized by an increased mucus burden and inflammatory markers without infection or structural lung disease and suggest that mucolytic and anti-inflammatory agents should be explored as preventive therapy.


2007 ◽  
Vol 42 (3) ◽  
pp. 256-262 ◽  
Author(s):  
Hara Levy ◽  
Leslie A. Kalish ◽  
Ian Huntington ◽  
Nathaniel Weller ◽  
Craig Gerard ◽  
...  

2009 ◽  
Vol 10 (3) ◽  
pp. 162-167 ◽  
Author(s):  
Enza Mozzillo ◽  
Adriana Franzese ◽  
Giuliana Valerio ◽  
Angela Sepe ◽  
Ilaria De Simone ◽  
...  

2001 ◽  
Vol 10 (2) ◽  
pp. 61-67 ◽  
Author(s):  
Galina V. Shmarina ◽  
Alexander L. Pukhalsky ◽  
Svetlana N. Kokarovtseva ◽  
Daria A. Pukhalskaya ◽  
Elena A. Kalashnikova ◽  
...  

Background: The life expectancy of patients with cystic fibrosis (CF) is largely dependent on the pulmonary disease severity and progress. Malnutrition may be an important complicating factor in active and chronic lung disease.Aims: The focus of this study was to investigate several inflammatory markers in pancreatic-insufficient CF patients with different enzyme treatment regimens.Methods: CF patients with pancreatic insufficiency were examined at a time of symptomatic exacerbation of their lung disease. Group A (n= 11) regularly received microspheric enzymes. Group B (n= 8) were treated with enzymes during the hospitalization period only and demonstrated the presence of malnutrition. Inflammatory markers in the sputa (neutrophil elastase activity, interleukin-8 and tumour necrosis factor-α levels) and in the peripheral blood (plasma malondialdehyde (MDA), lymphocyte response to PHA, and the cell sensitivity to steroid suppression) have been investigated.Results: During acute lung exacerbation, group B demonstrated reduced levels of lymphocyte proliferation. This parameter was normalized after combined antibiotic and pancreatic enzyme therapy. Simultaneously, plasma MDA in group B markedly increased following treatment. For this group, a significant positive linear association between values of plasma MDA and lymphocyte proliferation has been observed. For group A, neither the same correlation nor changes in MDA levels and lymphocyte proliferation have been found.Conclusions: Our data indicate that acute lung exacerbation in malnourished CF patients may be associated with alteration in T-lymphocyte activity. Adequate therapy normalizes lymphocyte function but results in systemic oxidative stress.


2014 ◽  
Vol 21 (4) ◽  
pp. e63-e66 ◽  
Author(s):  
Shahid I Sheikh ◽  
Karen McCoy ◽  
Nancy A Ryan-Wenger ◽  
Alpa Patel ◽  
Stephen Kirkby

BACKGROUND: Some patients with cystic fibrosis (CF) develop severe but localized lung disease or recurrent hemoptysis/pneumothorax refractory to conventional medical therapies.METHODS: The outcomes of lung resection in patients with CF and worsening localized lung disease or recurrent hemoptysis/pneumothorax refractory to conventional therapy (n=15) were evaluated by reviewing the medical records of all patients with CF followed at the CF Center at Nationwide Children’s Hospital (Columbus, Ohio, USA), who underwent lobectomy over a 15-year period (1998 to 2012).RESULTS: The median age of the 15 patients (93% Caucasian) was 20 years (range two to 41 years) and their mean forced expiratory volume in 1 s (FEV1) was 59.5% of predicted one year before surgery. Three patients died within two years after lobectomy; all three deaths occurred in patients with an FEV1≤40% of predicted before surgery. There were no significant changes in mean height, weight, body mass index, hospital admissions or antibiotic use over time. The mean FEV1decreased over time. Compared with at surgery, decline in FEV1in the year before surgery was −5.4% (P=0.024) and decline in the year after surgery was −1.3% (P=0.513); however, the difference in the rate of decline was not statistically significant.CONCLUSION: In patients with CF and localized worsening bronchiectasis and/or recurrent hemoptysis/pneumothorax, lobectomy carried a significant risk of mortality, especially in patients with FEV1≤40% of predicted, and should only be considered when all other measures fail.


Sign in / Sign up

Export Citation Format

Share Document